Gene study aims to personalize lung cancer drug therapy

NCT ID NCT05987956

Ongoing Knowledge-focused Sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This study looks at how tiny genetic differences (called SNPs) in ALK-positive non-small cell lung cancer patients might influence how well the drug alectinib works and what side effects occur. Researchers will analyze DNA from 600 patients who have been taking alectinib for at least 90 days. The goal is to better understand why some people respond differently to the same treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Medicine Invention Design, Inc. - IORG0007849 - NPI 1023387701

Rockville, Maryland, 20853, United States
Omnicure Clinical Research

Doral, Florida, 33172, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.